Every 8-K that Dermata Therapeutics Inc (DRMA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow DRMA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DRMA filings page.
Dermata Therapeutics, Inc. entered into securities purchase agreements for a private placement of an aggregate of 2,293,608 shares of common stock (or pre-funded warrants in lieu thereof), plus accompanying Series E and short-term Series F warrants, at $1.46 per share (or pre-funded warrant) and accompanying warrants. The transaction is expected to generate gross proceeds of approximately $3.4 million and net proceeds of about $3.2 million, with up to approximately $6.7 million of additional gross proceeds if all Series E and Series F warrants are exercised for cash. Company insiders, including the CEO and CFO, are participating at $1.47 per share (or pre-funded warrant) and accompanying warrants for about $2.4 million. The warrants become exercisable upon stockholder approval, with Series E expiring five years and Series F expiring twenty-four months after that approval. Dermata plans to use the proceeds for general corporate purposes, including launch and marketing of its new direct-to-consumer skincare products and potential acquisitions or licensing opportunities.
Dermata Therapeutics reported second quarter 2026 results and detailed its pivot to a commercial-stage, direct-to-consumer skincare model centered on its Tome™ line. The company plans to launch its first product, Tome Foundational Treatment, on August 25, 2026, aiming to begin generating product revenue.
For the quarter ended June 30, 2026, Dermata reported a net loss of $2.97 million, compared with $1.70 million a year earlier, as selling, general and administrative expenses rose to $2.80 million from $1.16 million, driven by higher legal, marketing, commercialization, and employee costs. Research and development expenses declined to $0.21 million from $0.62 million as resources were reallocated toward commercialization. Cash and cash equivalents were $4.4 million as of June 30, 2026, versus $7.5 million at year-end 2025, and the company expects its current cash to fund operations into the fourth quarter of 2026.
Dermata Therapeutics, Inc. disclosed that its first commercial product, the Tome Foundational Treatment, is expected to launch soon. The company expects the Foundational Treatment to be available for sale starting August 25, 2026, with customers on a waitlist receiving early access to preorder.
The Foundational Treatment set comprises four once-weekly treatments, sold exclusively through www.tomeskincare.com for $178, described as about $45 per treatment. The company also includes forward-looking statements about a strategic shift to commercialize skincare products and potential benefits such as accelerating commercialization, reducing regulatory burdens, and expanding into broader consumer markets, subject to risks outlined in its SEC reports.
Dermata Therapeutics, Inc. reported the results of its 2026 annual meeting of stockholders, where all management proposals were approved. Stockholders amended the 2021 Omnibus Equity Incentive Plan to increase the maximum aggregate number of shares reserved for issuance under the plan to 402,214 shares.
They also approved, for Nasdaq Listing Rule 5635(d) purposes, the issuance of common shares underlying certain warrants in an amount equal to or in excess of 20% of the common stock outstanding immediately before those warrants were issued, as well as a repricing of warrants exercisable for up to 120,734 shares. Three Class II directors were elected, the independent auditor for the year ending December 31, 2026 was ratified, and an adjournment proposal was approved.
Dermata Therapeutics reported first quarter 2026 results while continuing its shift from drug development to direct-to-consumer skincare under the new Tome brand. The company plans a mid-2026 launch of its once-weekly Tome Foundational Treatment mask for skin renewal.
Dermata ended March 31, 2026 with $6.9 million in cash and cash equivalents and raised $2.0 million in net proceeds through an at-the-market financing facility. Research and development expenses fell to $0.4 million from $1.3 million a year earlier, while selling, general and administrative expenses increased to $1.5 million from $1.1 million, mainly from marketing, audit, and legal costs. Net loss narrowed to $1.8 million, or $0.48 per share, compared with $2.3 million, or $4.47 per share, and the company expects its cash to fund operations into the first quarter of 2027.
Dermata Therapeutics reported 2025 results and detailed a strategic pivot from prescription dermatology to direct-to-consumer skincare under its new Tome brand. The first Tome product, a once-weekly Foundational Treatment mask, is planned for launch in the middle of 2026, with a Clearing Treatment for acne expected to follow.
For 2025, Dermata posted a net loss of $7.6 million, improving from a $12.3 million net loss in 2024, as research and development expenses declined to $2.9 million from $8.2 million, largely after completing its STAR-1 acne study. Selling, general and administrative expenses rose to $4.8 million from $4.3 million, mainly due to increased marketing.
Cash and cash equivalents were $7.5 million as of December 31, 2025, up from $3.2 million a year earlier, driven by approximately $12.1 million of net financing proceeds and $7.8 million of cash used in operations. Dermata raised $15.4 million in gross proceeds during 2025 and early 2026 and expects its cash to fund operations into the first quarter of 2027 while it prepares multiple Tome products for market.
Dermata Therapeutics, Inc. reported that director Mary Fisher has notified the company she will resign from its Board of Directors, including all committee roles, effective March 31, 2026. The filing states her decision is tied to her employer’s recent acquisition, which will no longer permit her to serve on Dermata’s board.
The company notes that her resignation is not due to any disagreement with Dermata or its management regarding operations, policies, or practices. Once her resignation becomes effective, the size of the Board will be reduced from eight to seven members.
Dermata Therapeutics, Inc. filed an 8-K describing a change in its independent registered public accounting firm. On January 30, 2026, the company dismissed Baker Tilly US, LLP as auditor, effective January 31, 2026, following approval by the Audit Committee of the Board of Directors.
Baker Tilly’s audit reports for the years ended December 31, 2024 and 2023 contained no adverse or disclaimed opinions and were not qualified, other than an explanatory paragraph raising substantial doubt about Dermata’s ability to continue as a going concern. The company states there were no disagreements with Baker Tilly and no reportable events during those periods.
On February 2, 2026, the Audit Committee approved the appointment of CBIZ CPAs P.C. as Dermata’s new independent registered public accounting firm. CBIZ CPAs had previously served as Dermata’s auditor from 2016 to 2023, and the company reports no consultations with CBIZ CPAs on accounting or audit matters during 2024, 2023, or through January 31, 2026.
Dermata Therapeutics, Inc. filed a prospectus supplement on January 27, 2026 to increase the maximum aggregate offering amount of its common stock issuable under its existing at-the-market offering program with H.C. Wainwright & Co., LLC by an additional $705,000.
The company previously sold $3,454,390 of common stock under the same Sales Agreement and earlier prospectus supplements. The filing also includes a legal opinion from Lowenstein Sandler LLP covering the additional $705,000 of common stock, which is provided as an exhibit.
Dermata Therapeutics, Inc. announced that it has elected to terminate its License Agreement with Villani, Inc., with the termination becoming effective 90 days after Villani receives the notice. This move is tied to Dermata’s recent strategic shift toward commercializing over-the-counter skin care treatments and its withdrawal of the XYNGARI™ investigational new drug application with the U.S. Food and Drug Administration.
Under the original agreement, Villani had granted Dermata an exclusive, sub-licensable, royalty-bearing license to develop and sell sponge-based pharmaceutical products for skin diseases and conditions. Dermata had agreed to pay up to $40.5 million in future development and sales milestone payments, plus single-digit royalties on net sales. After the termination date, Villani will not receive further milestone or other payments, Dermata’s development and commercialization obligations for licensed products will end, and the Villani licenses will cease to be in effect.
Dermata Therapeutics, Inc. furnished an 8-K announcing a press release with a corporate update and financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1, titled “Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results.”
The information under Item 2.02 and Exhibit 99.1 is furnished, not deemed filed under Section 18 of the Exchange Act, and is not incorporated by reference unless expressly stated.
Dermata Therapeutics filed an 8-K announcing it has filed a prospectus supplement to increase the maximum aggregate offering amount of common stock issuable under its At The Market Offering Agreement with H.C. Wainwright & Co., LLC by $1,792,315.
The company previously sold $1,662,142 of common stock under this agreement pursuant to a prior prospectus supplement. The filing also includes a legal opinion covering the additional $1,792,315 of shares tied to the Current Prospectus Supplement.
Dermata Therapeutics reported new clinical data from its Phase 3 STAR-1 trial of XYNGARI™ (DMT310) for acne, presented in an abstract at the 2025 European Academy of Dermatology and Venereology Congress. In an intent-to-treat analysis, XYNGARI showed statistically significant improvements versus placebo in multiple measures, including Investigator Global Assessment (IGA) treatment success, inflammatory lesion counts, and non-inflammatory lesion counts at weeks 4, 8, and 12.
For IGA treatment success defined as a 2-point reduction and a score of 0 or 1, XYNGARI achieved 29.4% of patients at week 12 compared with 15.2% on placebo. XYNGARI also had greater mean and percent reductions from baseline in both inflammatory and non-inflammatory lesion counts across all time points, supporting a consistent efficacy benefit over placebo in this Phase 3 acne study.